Superparamagnetic nanovector with anti-cancer properties: γFe2O3@Zoledronate

被引:46
作者
Benyettou, Farah [1 ]
Lalatonne, Yoann [1 ,2 ]
Sainte-Catherine, Odile [1 ]
Monteil, Maelle [1 ]
Motte, Laurence [1 ]
机构
[1] Univ Paris 13, Lab CSPBAT FRE 3043, CNRS, F-93017 Bobigny, France
[2] Hop Avicenne, Nucl Med Serv, F-93009 Bobigny, France
关键词
Drug nanoparticle; Magnetic nanoparticle; Bisphosphonate; Cancer drugs; Drug targeting; Cell internalization; BONE METASTASES; ZOLEDRONIC ACID; BISPHOSPHONATES; THERAPY; RESORPTION; BREAST;
D O I
10.1016/j.ijpharm.2009.04.010
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
We elaborate a magnetic nanovector to vectorize Zoledronate, an anti-cancer interest molecule of the hydroxmethylenebisphosphonate's family. In fact, Zoledronate is a powerful adjuvant in the treatment of bone diseases such as osteoporosis and Paget's disease. But, recent studies have shown that in addition to anti-osteoclastic properties, it presents antitumour properties notably in the case of breast and prostate cancer. However, these properties cannot be exploited due to their very high affinity to divalent cations and their preferentially accumulation in bone. To overcome this problem, one strategy is the vectorization trough maghemite nanocrystal functionalization. The specific surface coating permits to consider gamma Fe2O3@Zoledronate as a drug delivery vehicle for therapeutic activity. The anchoring to the nanoparticle's surface allowed to increase their hydrophobicity and also to change the therapeutic target, increasing the Zoledronate intestinal absorption instead of their accumulation in bone. We show that Zoledronate link the nanoparticle surface through phosphonate groups. The biological in vitro tests performed on breast cancer cell line, MDA-MB 231, showed that gamma Fe2O3@Zoledronate have anti proliferative activity. In addition, the gamma Fe2O3 core could be used as MRI contrast agent for a good therapeutic evaluation. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:324 / 327
页数:4
相关论文
共 14 条
[1]
Boissier S, 2000, CANCER RES, V60, P2949
[2]
Antitumor effects of bisphosphonates [J].
Green, JR .
CANCER, 2003, 97 (03) :840-847
[3]
Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption [J].
Green, JR ;
Rogers, MJ .
DRUG DEVELOPMENT RESEARCH, 2002, 55 (04) :210-224
[4]
Mesoscopic structures of nanocrystals: Collective magnetic properties due to the alignment of nanocrystals [J].
Lalatonne, Y ;
Motte, L ;
Russier, V ;
Ngo, AT ;
Bonville, P ;
Pileni, MP .
JOURNAL OF PHYSICAL CHEMISTRY B, 2004, 108 (06) :1848-1854
[5]
Bis-phosphonates - ultra small superparamagnetic iron oxide nanoparticles: a platform towards diagnosis and therapy [J].
Lalatonne, Yoann ;
Paris, Celine ;
Serfaty, Jean Michel ;
Weinmann, Pierre ;
Lecouvey, Marc ;
Motte, Laurence .
CHEMICAL COMMUNICATIONS, 2008, (22) :2553-2555
[6]
Lipton Allan, 2000, Cancer, V88, P3033, DOI 10.1002/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.3.CO
[7]
2-3
[8]
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite [J].
Nancollas, G. H. ;
Tang, R. ;
Phipps, R. J. ;
Henneman, Z. ;
Gulde, S. ;
Wu, W. ;
Mangood, A. ;
Russell, R. G. G. ;
Ebetino, F. H. .
BONE, 2006, 38 (05) :617-627
[9]
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion [J].
Rosen, LS ;
Gordon, DH ;
Dugan, W ;
Major, P ;
Eisenberg, PD ;
Provencher, L ;
Kaminski, M ;
Simeone, J ;
Seaman, J ;
Chen, BL ;
Coleman, RE .
CANCER, 2004, 100 (01) :36-43
[10]
Determinants of structure-function relationships among bisphosphonates [J].
Russell, R. Graham G. .
BONE, 2007, 40 (05) :S21-S25